 Home > Active Ingredient News > Antitumor Therapy > SMC approves the first immunotherapy combination (Nivolumab combined with ipilmumab) for patients with rare-mutated advanced colorectal cancer

SMC approves the first immunotherapy combination (Nivolumab combined with ipilmumab) for patients with rare-mutated advanced colorectal cancer

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

nodular acne treatment

quercetin health benefits

termite treatment tucson

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Nivolumab combined with ipilmumab has been approved by the Scottish Medicines Federation (SMC) as a treatment option for adult patients for the treatment of patients who have failed previous fluoropyrimidine-based chemotherapy

Recently, Bristol-Myers Squibb (BMS) announced that the Scottish Pharmaceutical Union (SMC) has accepted Nivolumab in combination with ipilmumab as a late mismatch repair defect (dMMR) or high microsatellite instability (MSIH)Treatment options for adults with colorectal cancer , these patients have failed previous fluoropyrimidine-based chemotherapy, and the therapy is used by the NHS in Scotland

Colorectal cancer

This group of patients is characterized by a rare genetic mutation called MSI-H or dMMR, which affects how the cancer grows

diagnosis

The median age of the treated patients was 66 years (N = 45)

The objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.

Original source:

https:// href="https://" target="_blank" rel="noopener">https:// https://

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.